Validation of 70-gene MammaPrint Profile in Japanese Population
By using gene-expression profiling, Van't Veer and colleagues developed a 70-gene prognosis profile, MammaPrint, to identify breast cancer patients who are at low risk of developing distant metastases and therefore might safely be spared chemotherapy. The aim of this study is to evaluate the prognostic value of the 70-gene Mammaprint profile in Japanese women with node-negative breast cancer.
|Study Design:||Observational Model: Cohort
Time Perspective: Retrospective
|Official Title:||Validation 70-gene MammaPrint Profile in Japanese Population|
- The probability of recurrence free survival (PRFS) [ Time Frame: 5 years ] [ Designated as safety issue: No ]
|Study Start Date:||April 2008|
|Study Completion Date:||January 2009|
|Primary Completion Date:||January 2009 (Final data collection date for primary outcome measure)|
Frozen tumor samples from 140 node-negative, breast cancer patients aged between 29 and 70 years at diagnosis are hybridized on MammaPrint array. Patients were treated with breast conserving therapy or mastectomy with axillary lymph node dissection between December 1998 and August 2001 at Osaka Medical Center for Cancer and Cardiovascular Diseases. Samples are evaluated by gene expression profiling for the 70-gene MammaPrint profile and classified as genomic high risk or genomic low risk.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00904566
|Osaka Medical Center for Cancer and Cadiovascular Diseases|
|Study Chair:||Kikuya Kato, MD, PhD, Prof||Osaka Medical Center for Cancer and Cardiovascular Diseases|